NCT03116685 - A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

April 15, 2021

Study Completion Date

April 15, 2021

Conditions

Primary Hyperoxaluria

Interventions

BIOLOGICAL

Oxabact OC5 - Oxalobacter formigenes HC-1

Active study drug

OTHER

Placebo

Trial Locations (10)

Charles Nicolle University Hospital, Tunis

Hédi Chaker University Hospital, Sfax

Sahloul University Hospital, Sousse

Vanderbilt University Hospital, Nashville

Kindernierenzentrum Bonn, Bonn

Hôpital Robert Debré, Paris

Centre Hospitalier Universitaire de Liège, Liège

Hospital Vall d' Hebron, Barcelona

Royal Free Hospital, London

Nottingham Children's Hospital, Nottingham